
DISRUPTING, REIMAGINING, AND REDEFINING THE
PRESCRIPTION DRUG INDUSTRY.

WE ARE NP2: NONPROFIT PHARMA.



EXECUTIVE SUMMARY:

NP2, a 501(c)(3) nonprofit organization, seeks to raise a total of \$3.5M (\$1M raised to date) to develop, manufacture, and distribute cyclophosphamide, an injectable oncology drug used to treat many cancers, including:

- Breast
- Ovarian
- Childhood Leukemia & Lymphoma
- Retinoblastoma

NP2 will lower the price of cyclophosphamide by ~35% and prioritize sales to NCI-designated cancer centers that serve a high proportion of patients who are uninsured, underinsured, and/or living on a fixed income.

NP2 will donate 10% of net sales to direct patient assistance funds to help provide additional financial assistance to cancer patients most in need.

NP2 is funded by donations, grants, and interest-bearing loans made by accredited lenders. Join us as we work to disrupt and fix the broken generic drug marketplace in the US.

WHAT IS NP2?



NP2 is an Agent for Change. We are:

- A nonprofit pharmaceutical corporation that puts patients ahead of profits.
- Committed to providing lower prices and a safe and steady supply of life-saving generics by manufacturing in the USA.
- A dedicated team of scientists, lawyers, doctors, entrepreneurs, and pharmaceutical industry experts with over 150 years of combined experience.
- Tackling some of the healthcare sector's biggest crises today.
- Self-funding after our first generic drug goes to market.

THE PROBLEM: FOR-PROFIT DRUG MANUFACTURERS FAIL TO MEET THE PROMISE OF THE GENERIC MARKETPLACE.

More than 20% of generic drugs had price increases of 100% or more in recent years.

Many drugs had increases of 1000% in price from 2010-2015.

Manipulation of price & supply contributes substantially to the healthcare crisis in the U.S.

Consolidation of generic companies has limited competition.

More manufacturers are exiting than entering the market, resulting in drug shortages.

THE RISING COST OF CARE LEAVES MANY PATIENTS BEHIND



Escalating Generic Drug Prices Impact Patients

30% of Patients in the USA have not taken medications as prescribed due to the cost.

58 million American adults have experienced medication insecurity in the last 12 months.



The High Cost of Cancer Treatment in America

\$167,904 = the average cost for one year of cancer treatment in 2019 in the U.S. This makes it difficult for most patients to afford their copays.

25% of US cancer patients skip doses of prescribed meds due to price.

RECENT HEADLINES IN THE NY TIMES POINT TO THE FAILURE OF THE GENERIC DRUG MARKETPLACE.

The New York Times | <https://www.nytimes.com/2023/06/26/health/cancer-drugs-shortage.html>

How the Shortage of a \$15 Cancer Drug Is Upending Treatment

Older generic chemotherapy drugs remain scarce, forcing doctors to put a priority on the patients who have the best chance of survival.

The New York Times | <https://www.nytimes.com/2023/03/22/health/drug-shortages.html>

Rising Rate of Drug Shortages Is Framed as a National Security Threat

A Senate homeland security committee examined growing health care shortages amid reports of rationing within hospitals.

The New York Times | <https://www.nytimes.com/2023/05/17/health/drug-shortages-cancer.html>

Drug Shortages Near an All-Time High, Leading to Rationing

A worrisome scarcity of cancer drugs has heightened concerns about the troubled generic drug industry. Congress and the White House are seeking ways to address widespread supply problems.

NEW MODELS IN THE PHARMA LANDSCAPE:

Mark Cuban Cost Plus Drugs:

- + An online pharmacy selling predominantly direct to consumer
- + Is a for-profit company
- + Emphasis on oral dose generic medications

NP2:

- + Sells to healthcare delivery systems NOT direct to consumer
- + A tax-exempt 501(c)(3) nonprofit org. Funded by tax-deductible donations and loans.
- + Focused on lowering the cost of generic injectable oncology drugs

Civica Rx:

- + Sells only to hospitals in its membership network
- + Funded through member hospitals and grants
- + Focus is on addressing drug shortages in hospitals




**NP2 WILL REDUCE THE PRICE
OF LIFE-SAVING GENERIC
ONCOLOGY DRUGS BY ~ 35%**



**INITIAL SALES WILL BE
TARGETED TO NCI-FUNDED
CANCER CENTERS, WHICH ARE
MANDATED TO REDUCE THEIR
COSTS**



**AS A NONPROFIT
ORGANIZATION, THERE ARE
NO SHAREHOLDERS TO
PRESSURE US TO RAISE PRICES**



**WE WILL REINVEST NET
REVENUES INTO DEVELOPING
ADDITIONAL LOWER-PRICED
LIFE-SAVING DRUGS**

**OUR SOLUTION:
PUT PATIENTS AHEAD OF PROFITS.**




CYCLOPHOSPHAMIDE—NP2'S RATIONALE AND LAUNCH STRATEGY:

Our first product, cyclophosphamide, the generic for the oncology drug Cytosan, has been FDA-approved for over 40 years yet has seen a 20-fold price hike since 2004. The generic, cyclophosphamide, is a mainstay drug used in Car-T Cell therapy and also in chemotherapy for many cancers including:



CYCLOPHOSPHAMIDE—AVERAGE WHOLESALE PRICE ANALYSIS 2004-2023:



NP2'S DIRECT IMPACT ON ONCOLOGY PATIENTS IN THE U.S:




PATIENTS PAY LESS:

- When hospitals pay less for drugs, insurance companies are billed less, and patient co-pays are reduced.

PATIENT ASSISTANCE FUNDS:


- NP2 will donate 10% of every vial of cyclophosphamide that we sell. In our first five years of sales, we project to contribute close to \$6 Million in direct patient assistance to those with financial need.
- NP2 may support patient assistance funds within hospitals that purchase from us, and we will partner with nonprofit patient assistance funds to offset the costs of treatment, housing, and travel, for individuals with the greatest financial need.

PROJECTED CYCLOPHOSPHAMIDE NET SALES: YEARS 1-5



TIMELINE TO GET TO MARKET: ~24 MONTHS

(The timeline begins once both parties have signed all legal agreements. Anticipated to be in Q2 2024.)



NP2'S END GOALS:

- **Help fix our broken prescription drug marketplace by demonstrating the important role of nonprofit pharma corporations like NP2.**
- **Bring about equity in healthcare by mitigating the forces that keep drug prices high.**
- **Address supply chain, drug safety, and shortage issues by manufacturing drugs here in the U.S.A.**



HELP CREATE LASTING CHANGE BY SUPPORTING NP2.

In nine months, NP2 raised \$1M of the \$3.5M needed to bring cyclophosphamide to market.

The next \$50,000 raised will be matched dollar for dollar!

Your gift today is a gift in perpetuity. You can leave a lasting legacy for current & future generations.

Support NP2—a 501(c)(3) Nonprofit corporation— by making a tax-deductible donation.

You can donate directly, through a donor-advised fund or family foundation, or by transferring appreciated shares of stock or other assets.


If you are an accredited lender, you can make a loan of \$5,000 or more to our wholly-owned LLC subsidiary, NP2-Fig Pharma.

Loans earn 10% simple, non-compounding interest.


** Donors and lenders who provide support in the amount of \$5,000 or more will be included in our Founders Circle.*

Principal and interest payments will begin on the date that is 14 months after the end of the fiscal year that NP2 achieves \$5 million in net revenue from sales of pharmaceutical products (re-payment is projected to start in year three post-market launch).

NP2: LEADERSHIP EXPERTISE AND A BOLD VISION FOR CHANGE



CEO & Co-Founder, William Buhles, Ph.D, is a pharmaceutical scientist with a three-decade track record of success as a clinical leader in bringing life-saving medicines to market. Dr. Buhles designed and ran Phase I, II, and III clinical trials in virology, oncology, and transplantation and oversaw later stages of drug development, including authoring and submitting new drug applications to the FDA and European Union.



Vice President & Co-Founder, Dr. Jay Lalezari is the CEO and Director of Quest Clinical Research in San Francisco and has served as a principal investigator for Phase I, II, and III clinical studies of new therapies for viral diseases including HIV/AIDS, CMV, HPV, HSV, Hepatitis B & C, Influenza, RSV and cancer. His work has been published extensively and he is a well-regarded international speaker and patient advocate.



Executive Director Terri Miller, MA, brings more than 30-years of leadership experience in the nonprofit sector with expertise in strategic planning, scaling organizations, marketing, fundraising, and operations. In more than three decades in the field, Terri has made her mark as a Development & Communications Director, Executive Director, Strategic Consultant, and Board President.



Chief Manufacturing Officer, Kevin Bittorf, Ph.D, is an accomplished senior executive with demonstrated success in pharmaceutical development and manufacturing from feasibility to commercialization. He has also played a key role in the implementation of innovative technologies and securing licensing deals, resulting in bringing more than 30 products to market..

CONTACT US FOR MORE INFORMATION:

**We Would Love to Hear From You.
Please Reach out to Learn More.**

- **William Buhles, Ph.D., Co-Founder, CEO, and Board President: (415)-518-0533; w.buhles@np2.org**
- **Terri Miller, Executive Director & Board Director: (415)-602-4281; t.miller@np2.org**
- **Learn more about NP2 online: www.np2.org**

MAKE A LASTING IMPACT & JOIN WITH NP2 IN CHANGING THE FACE OF PRESCRIPTION DRUG CARE IN AMERICA.

